Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2023-09-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
独立董事关于第六届董事会第八次会议相关议案的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' opinion on various proposals related to a specific capital raising event by Harbin Yuheng Pharmaceutical Co., Ltd. It discusses the legality, compliance, and fairness of a simplified procedure for a targeted stock issuance in 2023. The content focuses on the independent directors' review and approval of the issuance process, pricing, agreements, and related reports. This is not a full financial report, earnings release, or management discussion, but rather an official opinion related to a capital raising transaction. The document length is relatively short (2459 characters) and it is a formal announcement of independent directors' opinions on a capital issuance. Therefore, the best fitting category is Capital/Financing Update (CAP).
2023-09-19 Chinese
2023年度以简易程序向特定对象发行股票募集资金使用可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the feasibility analysis of the use of funds raised through a simplified procedure private placement of shares in 2023. It includes extensive information on the planned use of the raised funds, project descriptions, investment amounts, market analysis, and regulatory policy references. The content focuses on capital raising, fund allocation, and investment projects, particularly in drug development and repayment of bank loans. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive details about the capital raising and fund usage, not merely an announcement or a brief summary. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not an Annual Report, Earnings Release, or other categories related to financial results or governance. Hence, the correct classification is Capital/Financing Update (CAP).
2023-09-19 Chinese
第六届董事会第八次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the eighth meeting of the sixth board of directors of Harbin Yuheng Pharmaceutical Co., Ltd. The content focuses on the approval of a specific capital raising activity: a simplified procedure for a private placement of shares to specific investors. It includes voting results, references to regulatory compliance, and mentions of related agreements and reports. The document does not contain financial statements or detailed financial performance data but rather decisions and approvals related to capital issuance and associated governance matters. It is not a full annual or interim report, nor an earnings release or audit report. The primary focus is on capital raising and related corporate actions. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (4603 characters) and detailed content support this classification rather than a brief announcement or a regulatory filing fallback.
2023-09-19 Chinese
独立董事关于第六届董事会第八次会议相关议案的事前认可意见
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the independent directors of Harbin Yuheng Pharmaceutical Co., Ltd. regarding their prior approval opinion on a board meeting proposal related to a simplified procedure private placement of shares to a specific investor. It discusses compliance with stock exchange listing rules and relevant laws, and the independent directors' endorsement of the transaction. The document is short (713 characters) and focuses on a specific capital issuance transaction involving related party transactions. It is not a full financial report, earnings release, or management discussion. It is an announcement related to capital raising and share issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-09-19 Chinese
募集资金使用管理制度
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金使用管理制度' which translates to 'Fundraising Capital Usage Management System'. It details the rules, procedures, and governance related to the management and use of funds raised by the company through securities issuance. The content includes regulatory references, internal controls, supervisory responsibilities, and reporting requirements related to the use of raised capital. There is no indication that this is an announcement of a report, nor does it contain financial statements or earnings data. It is a detailed internal policy document concerning capital management and usage, which aligns with updates or information about capital/financing activities rather than a financial report or regulatory filing. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (7501 characters) supports it being a substantive document rather than a brief announcement.
2023-09-19 Chinese
2023年度以简易程序向特定对象发行股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and proposal for a simplified procedure private placement of shares by Harbin Gloria Pharmaceuticals Co., Ltd. It includes extensive information about the issuance background, purpose, target investors, pricing, number of shares, use of proceeds, approvals, and impact on control. The document references regulatory compliance with Chinese securities laws and Shenzhen Stock Exchange rules. It is not a financial report, earnings release, or management discussion but a comprehensive issuance plan (pre-issuance proposal) for a capital raising event through a private placement of shares. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length and detail confirm it is the actual plan, not just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2023-09-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.